Although several DYRK1A inhibitors have been implemented for potential therapeutic use in neurological disorders, cancer, and diabetes, developing a DYRK1A inhibitor that performs selectivity towards beta cells while avoiding adverse reactions is a formidable undertaking. This evidence concerns the gene DYRK1A and nervous system disorder.